Novo increases fatty liver efforts: "We've seen some highly convincing data"

Pharmaceutical company Novo Nordisk expands its emphasis on the fatty liver disease NASH. There's a huge market, but no one has solved the puzzle yet.
Novo Nordisk Executive Vice President, Development Martin Holst Lange | Photo: Novo Nordisk / PR
Novo Nordisk Executive Vice President, Development Martin Holst Lange | Photo: Novo Nordisk / PR
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

Danish pharmaceutical company Novo Nordisk keeps powering ahead in its efforts to find the first drug in the world which can treat the serious fatty liver disease non-alcoholic steatohepatitis (NASH).

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading